特瑞普利单抗联合阿昔替尼对比舒尼替尼一线治疗晚期肾细胞癌:RENOTORCH随机、开放标签、III期研究
RENOTORCH研究纳入421例中/高危不可切除或转移性肾细胞癌患者,1:1随机接受特瑞普利单抗联合阿昔替尼或舒尼替尼一线治疗。中位随访14.6个月,联合组独立评审委员会评估的中位无进展生存期为18.0个月,舒尼替尼组为9.8个月(HR 0.65,95%CI 0.49-0.86;P=0.0028),客观缓解率分别为56.7%和30.8%(P<0.0001)。
要点
- 特瑞普利单抗联合阿昔替尼较舒尼替尼显著延长中/高危晚期肾细胞癌患者的无进展生存期。
- 联合组独立评审委员会评估的客观缓解率为56.7%,舒尼替尼组为30.8%。
- 联合组治疗相关≥3级不良事件发生率为61.5%,舒尼替尼组为58.6%。
核心结论
- 在既往未治疗的中/高危晚期肾细胞癌患者中,特瑞普利单抗联合阿昔替尼较舒尼替尼显著延长无进展生存期并提高客观缓解率,安全性可控。
研究设计与样本
- RENOTORCH是一项随机、开放标签、III期研究,纳入中/高危不可切除或转移性肾细胞癌患者,按1:1随机接受特瑞普利单抗联合阿昔替尼(n=210)或舒尼替尼(n=211)治疗。
主要发现
- 中位随访14.6个月,独立评审委员会评估的中位无进展生存期在特瑞普利单抗联合阿昔替尼组为18.0个月,舒尼替尼组为9.8个月(HR 0.65,95%CI 0.49-0.86;P=0.0028)。
- 独立评审委员会评估的客观缓解率在特瑞普利单抗联合阿昔替尼组为56.7%,舒尼替尼组为30.8%(P<0.0001)。
- 总生存期观察到倾向于特瑞普利单抗联合阿昔替尼的趋势(HR 0.61,95%CI 0.40-0.92)。
- 治疗相关≥3级不良事件发生率在特瑞普利单抗联合阿昔替尼组为61.5%,舒尼替尼组为58.6%。
关键数值与推荐
- 特瑞普利单抗240 mg静脉注射每3周一次,联合阿昔替尼5 mg口服每日两次。
- 舒尼替尼50 mg口服每日一次,服药4周休息2周(6周周期)或服药2周休息1周(3周周期)。
- 主要终点为独立评审委员会评估的无进展生存期,次要终点包括研究者评估的无进展生存期、客观缓解率、总生存期和安全性。
临床怎么用
- 对于既往未治疗的中/高危晚期肾细胞癌患者,特瑞普利单抗联合阿昔替尼较舒尼替尼显著延长无进展生存期并提高客观缓解率,安全性可控。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors are standard treatments for advanced clear cell renal cell carcinoma (RCC). This phase III RENOTORCH study compared the efficacy and safety of toripalimab plus axitinib versus sunitinib for the first-line treatment of patients with intermediate-/poor-risk advanced RCC. PATIENTS AND METHODS: Patients with intermediate-/poor-risk unresectable or metastatic RCC were randomized in a ratio of 1 : 1 to receive toripalimab (240 mg intravenously once every 3 weeks) plus axitinib (5 mg orally twice daily) or sunitinib [50 mg orally once daily for 4 weeks (6-week cycle) or 2 weeks (3-week cycle)]. The primary endpoint was progression-free survival (PFS) assessed by an independent review committee (IRC). The secondary endpoints were investigator-assessed PFS, overall response rate (ORR), overall survival (OS), and safety. RESULTS: A total of 421 patients were randomized to receive toripalimab plus axitinib (n = 210) or sunitinib (n = 211). With a median follow-up of 14.6 months, toripalimab plus axitinib significantly reduced the risk of disease progression or death by 35% compared with sunitinib as assessed by an IRC [hazard ratio (HR) 0.65, 95% confidence interval (CI) 0.49-0.86; P = 0.0028]. The median PFS was 18.0 months in the toripalimab-axitinib group, whereas it was 9.8 months in the sunitinib group. The IRC-assessed ORR was significantly higher in the toripalimab-axitinib group compared with the sunitinib group (56.7% versus 30.8%; P < 0.0001). An OS trend favoring toripalimab plus axitinib was also observed (HR 0.61, 95% CI 0.40-0.92). Treatment-related grade ≥3 adverse events occurred in 61.5% of patients in the toripalimab-axitinib group and 58.6% of patients in the sunitinib group. CONCLUSION: In patients with previously untreated intermediate-/poor-risk advanced RCC, toripalimab plus axitinib provided significantly longer PFS and higher ORR than sunitinib and had a manageable safety profile TRIAL REGISTRATION: ClinicalTrials.gov NCT04394975.
引用
- Yan XQ, Ye MJ, Zou Q, et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann Oncol. 2023. PMID: 37872020. doi:10.1016/j.annonc.2023.09.3108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。